February 7, 2019, MedPage Today 

A biosimilar to trastuzumab (Herceptin) demonstrated noninferiority versus the branded drug in a randomized trial of patients with metastatic HER2-positive breast cancer.

Treatment with Pfizer's biosimilar PF-05280014 plus paclitaxel led to objective responses in 62.5% of patients with metastatic HER2-positive breast cancer compared with 66.5% for European-sourced (EU) trastuzumab and the taxane, a difference that met statistical requirements for noninferiority. The two treatment groups had virtually identical progression-free survival (PFS), as reported in the British Journal of Cancer(BJC).